($36M in Series A Funding)

Therini Bio, Inc., a biotech company focused on developing fibrin-targeted therapies for inflammatory neurodegenerative and retinal diseases, announced the close of a $36M Series A financing round. 

The funding round was co-led by Dementia Discovery Fund, MRL Ventures Fund, the therapeutics-focused corporate venture fund of Merck & Co., Inc., Sanofi Ventures, and SV Health Investors’ Impact Medicine Fund. New investor Eli Lilly and Company participated in the round, alongside existing investors Alzheimer’s Drug Discovery Foundation (ADDF), Dolby Family Ventures, and Foundation for a Better World. The Series A funding brings the total amount raised since inception to $62M.